top of page

Post-conference summary 2021

All Videos

All Videos

Watch Now

It will include the exclusive VIP part of the conference, covering topics of "How to invest in longevity?", "How can you achieve longevity?", "Is society ready for longevity?" and "Biostasis".

 

If you have questions, please feel free to contact us.

It was a pleasure to welcome all of the participants to the Longevity Investors Conference! We hope that you enjoyed this experience.

For those who could not join or would like to learn more about this fascinating subject, which is longevity, we are preparing a video. 

Speakers 2021

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Sergey Young

Founder, Longevity Vision Fund

Sergey Young is a longevity investor and visionary with a mission to extend healthy lifespans of one billion people. To do that, Sergey founded Longevity Vision Fund to accelerate life extension technological breakthroughs and to make longevity affordable and accessible to all Sergey is on the Board of Directors of the American Federation of Aging Research (AFAR) and the Development Sponsor of AGE REVERSAL XPRIZE global competition designed to cure aging. Sergey is also a Top-100 Longevity Leader, who is transforming the world, one workplace at a time, with Longevity@Work – the first non-profit corporate longevity program of its kind.
Sergey Young has been featured as a top longevity expert and contributor on CNN, Fox News, and Forbes. As the author of books such as ‘The Science and Technology of Growing Young’ and the mastermind behind the online life extension platform SergeyYoung.com, Sergey is passionate about sharing news from the exciting world of longevity

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Brian Kennedy

Director at Centre for Healthy Longevity, National University Health System and Professor Departments of Biochemistry and Physiology, National University of Singapore

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Program, and (3) the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life. From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell.

Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Celine Halioua

Founder, Loyal

Celine is the founder and CEO of Loyal, a biotech startup developing drugs to extend dog lifespan. She is also dabble in biotech & deep-tech investing.

Before that, she was a D.Phil. student at Oxford studying the health economics of gene therapy (St Peter’s College) & Chief of Staff to Laura Deming at Longevity Fund. Celine studied neuroscience and nanobiotechnology at the University of Texas at Austin and Uppsala Universitet in Sweden. She worked in the laboratories of Dr. Evan Snyder at the Sanford Consortium of Regenerative Medicine on novel enteric neuron disease therapeutics, and of Dr. Richard Morrisett and Dr. Keith Stevenson at The University of Texas at Austin on the development of a novel fluorescent silver-nanocluster-based neuronal tracers.

She is interested in biotechnology, specifically unravelling and developing therapeutics for pathological aging. Celine is also interested in healthcare systems, specifically the application of socialized healthcare practices to the United States and the economic incentivization of preventative and curative medicine.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

James Peyer

Chief Executive Officer and Co-Founder, Cambrian Biopharma

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. He also serves as the Chairman of the Board of Sensei Biotherapeutics and board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Maria Konovalenko

Scientist in Residence, Formic Ventures

Maria Konovalenko is a Scientist in Residence at Formic Ventures, a diversified venture capital firm that makes early stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful. Maria’s obtained her PhD in biology of aging in a joint program between University of Southern California and the Buck Institute for Research on Aging. Her research was focused on aging of stem cells in respiratory epithelium as well as the overlap between mTOR signaling and cellular senescence.

Maria has been involved in fighting aging since 2008. She is one of the organizers of the Genetics of Aging and Longevity Conference series. Maria was part of team at the science for Life Extension Foundation, a Moscow-based non-profit, since 2008 to 2016 and has been raising funding for longevity and regenerative medicine research from both government and private sources.

Maria's background is in molecular biophysics, she got both her Bachelor's and Master's degrees from Moscow Institute of Physics and Technology. Maria's goal is to make people live as long and as healthy as possible using the advances of science and technology.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Dina Radenkovic

Co-founder & Chief Science Officer, Hooke

Dina is an academic medical doctor by background, working as an investor and entrepreneur in the field of aging. She is a General Partner at the Programmable Biology SALT Fund. She is a co-founder & Chief Science Officer Hooke, an elite longevity research clinic in London launched in partnership with Dr Eric Verdin from the Buck Institute for Research on Aging. She is also a senior scientist at the Buck Artificial Intelligence applied to the Biology of Aging Platform where they study novel biomarkers of biological aging.

Dina qualified with a dual degree in medicine and physiology from UCL Medical School, with the elective at the New England Journal of Medicine, Harvard University, awarded number one in preclinical medicine and the best overall performance in physiology BSc. She has led two projects, digital therapeutics company for women and an algorithm for cardiac MRI to major industry acquisitions. She later worked as Research Fellow at King's College London and at Harvard University. Dina did her residency at St Thomas’ Hospital in London. She has over 30 academic papers, 7 grants and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Wei-Wu He

Executive Chairman, Human Longevity

Dr. Wei-Wu He has been serving as Executive Chairman of Human Longevity Inc. since July 2019. Dr. He is currently the Chairman of CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder of Genetron Health; Dr. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000.
In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 50 research publications and inventor of over 32 issued patents.
Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Raiany Romanni

Researcher, Harvard Medical School

Raiany Romanni is a researcher in bioethics at Harvard Medical School (HMS), where she focuses on the ethical implications of longevity research conducted in HMS labs and beyond.

Raiany has published extensively on the subject of death, with articles in philosophical journals dealing with theories from Freud to Nietzsche, and most recently, the ABC article on the ethics behind life-extending technologies, which received nearly 100,000 views in one week. For her PhD dissertation in German Philosophy, at Brown University, she is working on a non-fiction book that investigates why 21st century, secular humans insist on narrating aging as a mystical, tabooed phenomenon.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Andrea B. Maier

Co-Director at Centre for Healthy Longevity, National University Health System; Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, National University of Singapore

Andrea Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier’s research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees. She currently is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Amutha Boominathan, Ph.D.

Group Lead, SENS Research Foundation

Amutha Boominathan is the Group Lead for the MitoSENS program at SENS Research Foundation, Mountain View, California. She received her PhD in Biochemistry from National Chemical Laboratory, Pune, India. She obtained further postdoctoral training through an American Heart Association Postdoctoral fellowship at the University of Pennsylvania and Rutgers University, where she studied mitochondrial biogenesis, particularly protein import into mitochondria and the fusion and fission mechanisms in the organelle.
Subsequently, she joined SENS Research Foundation as a Senior Research Scientist and currently leads the mitochondria research program in developing translational therapies to combat mtDNA mutations. Using patient derived cybrids and animal models the Boominathan lab is developing gene therapy and organelle replacement strategies to alleviate age-associated mitochondrial dysfunction. Dr Boominathan is passionate about applying her expertise in the longevity field to improve health outcomes in aging and age-related diseases.

  • LinkedIn
EMAIL.png
GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Morten Scheibye-Knudsen

Associate professor, University of Copenhagen

For Dr Scheibye-Knudsen, associate professor, University of Copenhagen, aging is the largest risk factor for most diseases and damage to our genome is likely the cause of aging. He is focused on exploring the physiological consequences of DNA damage and what we can do to intervene in genotoxic insults. His goal is to understand, modulate, and treat aging and age-related diseases.
Morten earned his MD in 2007 from the University of Copenhagen where he also earned his DMSc (Doctor of Medical Sciences, higher doctorate) in Neurodegeneration in Accelerated Aging in 2016.
In 2008, Morten became Postdoctoral Fellow in the laboratory of Vilhelm Bohr at the National Institute on Aging, NIH, in Baltimore, Maryland. His work focused on the cross-talk between DNA repair and mitochondrial function in neurodegeneration and aging. In 2013, at NIH, he became Research Fellow and in 2015, Visiting Professor.
For six years, Morten lectured on the Biological Basis of Aging for graduate students at Johns Hopkins Bloomberg School of Public Health.
In addition to his academic activities Morten manages his companies Forsoegsperson.dk and Mitodb.com, is a board member at the Longevity Vision Fund and Molecule Protocols, and serves as Chief Editor at Frontiers Media.

  • LinkedIn